Top Class Actions  |  September 13, 2019

Category: Closed Class Actions

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

This settlement is closed!

Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!

prescription for thalomid or revlimid cancer medication

UPDATE:

  • This class action settlement is paying out up to $1,968 as of July 6, 2022.
  • Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

A group of cancer patients, their families, and insurers have secured a $55 million class action settlement ending allegations that the maker of Thalomid and Revlimid conspired to keep cheaper, generic versions of the cancer drugs from entering the market.

Class Members include individuals in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, and Tennessee, who paid for the cancer treatment drugs Thalomid or Revlimid before Aug. 1, 2019.

Those who paid for the medication on behalf of another are also eligible.

Additionally, Class Members include insurance companies and other health and welfare companies who paid for or reimbursed individuals for the cancer treatment drugs in those states.

The Thalomid Revlimid antitrust class action alleged that Celgene Corporation withheld generic versions of cancer treatment drugs from the market in order to generate more profit.

The plaintiffs accused the company of forcing cancer patients and their loved ones to pay more for life-saving treatment, even though a generic version of the medication was available.

According to the International Myeloma Foundation, Thalomid is an immunomodulatory drug. This means that the drug affects the immune system and, in conjunction with other medications, is considered an effective treatment for multiple myloma — the first in decades when it was introduced in 2006, according to the Foundation.

Thalomid is thought to be a good alternative to Revlimid, an immune modulator, in patients with low blood cell counts.

Celgene produces both drugs and was hit with a number of lawsuits alleging antitrust behavior by both individual consumers and insurance companies. These Thalomid Revlimid antitrust class action lawsuits were consolidated into multidistrict litigation.

Celgene denies any wrongdoing, but has agreed to pay $55 million to end the Thalomid, Revlimid antitrust class action lawsuit.

Under the terms of the settlement, both individuals and third party payors can make claims. Class Members can claim a part of the settlement amount proportionate to their purchases of either Thalomid or Revlimid.

Both individuals and third party payors must submit a Claim Form either online or via mail. Documentation is not required, but the settlement administrator may ask for proof at a later date.

The deadline for Class Members to object to or opt out of the Thalomid Revlimid antitrust class action settlement is Dec. 2, 2019.

Who’s Eligible

Class Members include both individuals, insurance, and other health and welfare companies who “paid for all or some of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before August 1, 2019.”

Potential Award

Varies. Claims will vary depending on the purchases of the Class Member.

Proof of Purchase

Not required at this time. However, the settlement administrator may ask for proof later on.

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

12/30/2019

UPDATE: On December 23, 2019, the court was informed that pursuant to provisions in the settlement agreement, Celgene has decided to terminate the Thalomid and Revlimid Antirust settlement agreement. This means that claims will not be paid at this time. We appreciate your ongoing patience. Top Class Actions will continue to provide updates as we learn more.  

UPDATE 2: July 2020, a revised cancer medications price fixing class action settlement has been reached. Click here to file a claim and to learn more.

Case Name

 In re: Thalomid and Revlimid Antitrust Litigation, Case No. 2:14-cv-06997, in the U.S. District Court for the District of New Jersey

Final Hearing

1/6/2020

Claims Administrator

In re Thalomid and Revlimid Antitrust Litigation Settlement Administrator
c/o KCC Class Action Services LLC
PO Box 43143
Providence, RI
02941-3143

info@ThalomidRevlimidLitigation.com

Class Counsel

Melinda R. Coolidge
HAUSFELD LLP

Defense Counsel

John E. Schmidtlein
WILLIAMS & CONNOLLY LLP

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

19 thoughts onCancer Medication Price-Fixing Class Action Settlement

  1. Rosie says:

    $1,968 check received

  2. Member says:

    Informed delivery says something is in the mail… anyone received a check? How much?

  3. Update says:

    Dear Judge Arleo:
    Plaintiffs write to inform the Court that pursuant to paragraph 36 of the settlement
    agreement (ECF 289-3), Celgene informed Plaintiffs this morning that it is terminating the
    settlement agreement. 1 Therefore, Plaintiffs withdraw as moot their motion for final approval of
    settlement (ECF 294) and motion for attorneys’ fees, expenses, and service awards to the class
    representatives (ECF 293).

    Needless to say, Plaintiffs are disappointed that because some 80 class members
    exercised their right to exclude themselves from the class settlement, the approximately 9,000
    consumers and third-party payors that filed claims to participate in the $55 million settlement
    will be denied any compensation at this time.

    Plaintiffs’ renewed motion to certify the class was fully briefed in February 2019, and
    was pending decision prior to the parties’ announcement of a settlement agreement in July 2019.
    No objections were received to the class settlement. Plaintiffs respectfully request that the Court
    convert the January 6, 2020 Fairness Hearing to a status conference to discuss next steps.

  4. Henry Cruz says:

    MERRY CHRISTMAS SETTLEMENT IS OVER FOR THE TIME BEING EVEN ATTORNEYS ARE SCREWED FOR NOW LOL

  5. JROD says:

    Settlement agreement has been terminated.

    1. Josh says:

      source?

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.